Clinical Trials Directory

Trials / Completed

CompletedNCT02515097

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
213 (actual)
Sponsor
Bausch Health Americas, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).

Detailed description

The objective of the study is to evaluate the safety and efficacy of topical IDP-122 Lotion when applied once daily to adult participants with moderate to severe plaque psoriasis. The intent of the study is specifically to evaluate the safety and efficacy of a once daily application of IDP-122 Lotion in comparison with vehicle.

Conditions

Interventions

TypeNameDescription
DRUGIDP-122 LotionMedicated topical lotion
DRUGIDP-122 Vehicle LotionVehicle topical lotion with no active ingredient

Timeline

Start date
2015-11-05
Primary completion
2017-03-15
Completion
2017-03-15
First posted
2015-08-04
Last updated
2020-01-27
Results posted
2020-01-27

Locations

15 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02515097. Inclusion in this directory is not an endorsement.